

Executive and Council Members as of march 2007

Executive/Exécutif

President/Président (2005-07)	Teik Chye Ooi University of Ottawa
Past President/Président sortant (2005-07)	Avrum I. Gotlieb Banting Institute
President-Elect/Président désigné (2005-07)	Mark Hatton McMaster University
Secretary/Secrétaire (Interim, 2007)	André Tchernof Ctr Hosp. Univ. de Québec
Treasurer/Trésorier	Pierre Julien Ctr. Hosp. Univ. de Québec
Founding President/ Présidente fondatrice	M. Daria Haust

Councillors/Conseillers

Chair Education Committee (2004-07)	Bassam A. Nassar Dalhousie University
Chair Finance Committee (2006-09)	Edward R. O'Brien University of Ottawa
Membership Coordinator (2007-09)	Charles Couillard Laval University
Councillor/Conseiller (2005-08)	Sandra Davidge University of Alberta
Councillor/Conseiller (2005-08)	Scott Heximer University of Toronto
Councillor/Conseiller (2001-07)	Alexandra Lucas John P. Robarts Research
Councillor/Conseiller (2003-09)	Garry X. Shen University of Manitoba
Councillor/Conseiller (2006-09)	Stewart Whitman University of Ottawa

CANADIAN SOCIETY OF ATHEROSCLEROSIS,
THROMBOSIS AND VASCULAR BIOLOGY

SOCIÉTÉ CANADIENNE D'ATHÉROSCLÉROSE,
DE THROMBOSE ET DE BIOLOGIE VASCULAIRE

www.csatvb.ca

CSATVB



SCATBV

FALL NEWSLETTER

August, 2007

Editorial

The last edition of the Newsletter focused on young investigators and students. We clearly recognize that the younger members form a crucial component of the membership of our society, particularly at our scientific meetings. By comparison, the more senior members of the society, the PIs and co-PIs (whether clinical or basic scientists), seem to be less prominent, unfortunately. The annual meeting sees many young investigators, some with their supervisors, and members of the executive, but relatively few other senior members. Why has this happened? This is not an easy question to answer. Is this because the CSATVB is seen as an inadequate forum for the exchange of scientific information? The science at our meeting is leading edge, with world-class guest speakers and symposium participants. Conceivably, the program of events does not include your specialty? If this is the case, the society may be able to offer you the opportunity to suggest and even organize a symposium to focus on a topic of interest to you! Does it matter that senior scientists do not

attend the meeting? The presence of senior members at scientific meetings is crucial to the well being, if not the survival, of the society. Senior members by their activity, scholarship and reputation set an example to trainees and nurture their future professional behaviour. We appeal to senior researchers to get more involved with the society. Furthermore, as our society meets annually as part of the CCC, a unique opportunity presents itself to meet colleagues from a wide range of disciplines from all over Canada and beyond, and to participate in sessions covering the whole gamut of cardiovascular science. You never know, you may inadvertently meet and impress the reviewer of your next grant application!

In this issue, we are featuring Rob Hegele who is an excellent example of an accomplished senior scientist, has been an active member of CSATVB since 1989, and a Councillor from 1991 to 1994. We have also included a fragment of a long letter received from Dr. M. Daria Haust, the founding President of the Society, who announces her recent award of the Order of Canada from our Governor-general, Mme. Michaëlle Jean. We are sure that we speak for all members of the Society in offering Daria our heartfelt congratulations. "Flashback"

will include extracts from a biographical profile of the President elect, Mark Hatton, as it was presented in Spring, 1995, by Zafar Alavi, the Editor of the Newsletter at that time

We extend our sincere thanks to our outgoing President, Teik Ooi, who will be stepping down at the next Annual General Meeting (to be held on October 23 at the CCC Meeting in Quebec City). Teik has been the architect of a number of new initiatives for the Society and has gained great respect for his ability to relate to all our members, especially those who have recently joined the society (see the last issue of the newsletter). In these ways, Teik has been a most effective President. As Past President, Teik's advice and support will be most valuable to the incoming President and the Executive. We wish Teik well in all his future activities.

Finally, we have included in this issue the *unapproved* Minutes of the 2006 Annual General Meeting (held in Vancouver, October, 2006) in order that the wider membership of the society can review their contents and prepare any appropriate response for delivery at the upcoming AGM. We hope you enjoy the newsletter, and we look for input in any form, bouquets or brickbats!

Éditorial

La dernière édition du Newsletter a porté surtout sur les jeunes chercheurs et sur les étudiants. Nous constatons que les plus jeunes membres forment une partie cruciale de notre société, particulièrement à nos rencontres scientifiques. Malheureusement, les membres seniors de la société, les PIs et les co-PIs (que ce soit des chercheurs cliniciens ou fondamentaux), semblent beaucoup moins présents. Les rencontres annuelles attirent plusieurs jeunes chercheurs, certains avec leurs superviseurs, membres de l'exécutif, mais relativement peu de chercheurs seniors. Pourquoi est-ce ainsi? Ce n'est sûrement pas une question facile à répondre. Est-ce parce que la SCATVB est considérée comme présentant une tribune inadéquate aux échanges d'informations scientifiques? Nos rencontres sont à la pointe de la science en présentant aux symposiums des conférenciers d'envergure mondiale et des participants de qualité. Il n'est donc pas exclu que le contenu de nos événements ne réponde pas à votre spécialité. Si cela est le cas, la société aimerait vous offrir la possibilité de lui faire des suggestions ou même d'organiser un symposium traitant d'un sujet qui vous intéresse. Est-ce important que les membres seniors participent aux rencontres scientifiques? La présence des membres seniors est cruciale pour la bonne santé, si ce n'est pour la survie même de la société. Les membres seniors sont par leur activité, leur savoir et leur réputation des exemples pour les membres en formation ainsi qu'une inspiration pour leur carrière professionnelle future. Nous implorons les chercheurs seniors à accroître leur implication à l'intérieur de la société. Par ailleurs, étant donné que notre rencontre annuelle se tient lors de la CCC, cela représente une opportunité unique de rencontrer des collègues de d'autres disciplines à la grandeur du Canada ainsi que de pouvoir participer à des sessions couvrant un large éventail de la science cardiovasculaire. On ne sait jamais, vous

pouvez rencontrer par hasard et impressionner le critique de votre prochaine demande de subvention!

Dans cet édition, nous mettrons en lumière Robert Hegele qui est un excellent exemple d'un scientifique senior accompli, membre actif de la SCATVB depuis 1989 en plus d'en avoir été un conseiller de 1991 à 1994. Nous avons également inclus un fragment de la longue lettre reçue du Dre Daria Haust, fondatrice présidente de la société qui nous annonce sa récente distinction de l'Ordre du Canada reçu des mains de notre gouverneur général, Madame Michaëlle Jean.

Nous sommes certains de parler au nom de tous les membres de la société en offrant à Daria nos plus sincères félicitations. «Flashback», notre clin d'œil sur le passé inclura des extraits du profil biographique de notre président élu, Mark Hatton, tel que paru au printemps 1995, et présenté par Zafar Alavi, l'éditeur du Newsletter à ce moment là.

Nous exprimons également nos sincères remerciements à notre président sortant, Teik Ooi, qui terminera ses fonctions à la prochaine assemblée annuelle qui se tiendra le 23 octobre au CCC dans la ville de Québec. Teik a été l'architecte d'un grand nombre de nouvelles initiatives et a été reconnu pour son habilité à communiquer avec tous les membres, spécialement ceux qui ont récemment joint la société (voir la dernière édition du Newsletter). Teik a été un président très efficace. Comme président sortant, les conseils de Teik et son support seront très précieux pour le nouveau président et l'exécutif. Nous lui souhaitons bonne chance dans ses futures activités.

Finalement, nous avons inclus dans cette édition les Minutes non approuvées de la dernière assemblée générale tenue en Octobre 2006, à Vancouver de manière à ce qu'un plus grand nombre de membres puissent en réviser le contenu et se préparer à intervenir à la prochaine assemblée générale. Nous espérons que vous apprécierez le Newsletter et nous attendons vos commentaires de quelques manières que ce soit, louange ou critique.

Future Scientific Meetings of Interest to Members

Canadian Cardiovascular Congress (CCC); CCC 2007, October 20-24th in Quebec City, QU.

2007 Canadian Lipoprotein Conférence / 2007 Conference Canadienne sur les Lipoprotéines. Château Mont St Anne, Beauport, Québec October 11-14th 2007 [Further information: melanie@cianflonecommunication.com]

American Heart Association (AHA); Scientific Sessions, November 4-7th, 2007, in Orlando, FL.

9th International Symposium on Resistance Arteries; February 17-21, 2008, Hamilton Island, Australia.

International Symposium on Chylomicrons in Disease; March 6-8, 2008, in Lake Louise Alberta.

[CSATVB has agreed to co-sponsor this meeting]

North American Vascular Biology Organisation (NAVBO); "Vascular Biology" Meeting, April 5-9, 2008, San Diego, CA.

AHA "Arteriosclerosis, Thrombosis and Vascular Biology" Annual Conference; April 16-18th, 2008, in Atlanta, GA.

Leadership in Science Forum, Le Centre Sheraton Montreal Hotel, Montreal May 8-10, 2008

[More information at www.cihp.ca/e/8663.html]

15th International Vascular Biology Meeting; June 1-5th, 2008, in Sydney, Australia

International Atherosclerosis Society (IAS); XV International Symposium on Atherosclerosis; June 14-18th, 2008, in Boston, MA.

Canadian Cardiovascular Congress (CCC); CCC 2008, October 25-29th in Toronto, ON.

Vascular Matrix Biology and Bioengineering 2nd Workshop; March, 2009 in Whistler, BC.

International Society of Thrombosis and Haemostasis (ISTH); XXII Congress, July 11-17th, 2009, in Boston, MA.

Highlights included fascinating talks on the study of cell signal transduction in three-dimensional matrix, mechanotransduction in the vascular system, and the use of matrix to engineer biomaterials for cardiovascular regenerative medicine. On the translational research front, the mechanisms of vascular calcification were a strong focus, and there were state-of-the art presentations on imaging atherosclerosis, aneurysms and matrix proteolytic activity in live mice. Numerous awards to trainees (including some to CSATVB members) were presented including: Rani Cruz (University of British Columbia), Celine Bouvet (University of Montreal), Thanaphum Osathanon (University of Washington), Chinten Lim (UCSD), John Kirton (University of Manchester), Eric Ispanovic (York University), Matthew Frontini (Robart's Research Institute), and Feng Shi (University of Rochester). We were fortunate to receive generous

funding for trainee travel awards from The Heart and Stroke Richard Lewar Center of Excellence at the University of Toronto. University of Toronto award winners included: Cindy Yip, Pamela Ahmad, Winsion Chow, Edmond Young, Marc Chretien, Peter Sabatini, Chris Franco and Severa Bunda. In addition, Chinten



CSATVB/NAVBO winners.
Bottom row (left to right) Rani Cruz (UBC), Celine Bouvet (U Montreal), Thanaphum Osathanon (U Washington), Chinten Lim (UCSD).
Top row (left to right) John Kirton (U Manchester), Eric Ispanovic (York U), Matthew Frontini (UWO), Feng Shi (Rochester U).

Lim and Peter Sabatini won the outstanding poster awards. Mark your calendars for Whistler in March, 2009, when we will present VMBBE II!

Michelle P. Bendeck
Department of Laboratory Medicine & Pathobiology, University of Toronto



Lewar Center winners:
Bottom row (left to right) Cindy Yip, Pamela Ahmad, Winsion Chow.
Top row (left to right) Edmond Young, Marc Chretien, Peter Sabatini, Christopher Franco.

Biography Corner

Dr. Robert Hegele, MD, FRCPC, FACP



Rob Hegele is the Director of the Blackburn Cardiovascular Genetics Laboratory at Robarts Research Institute. For more than 20 years, his research has been focused on the discovery of genes that render people susceptible or resistant to heart disease, diabetes, high blood pressure and high cholesterol.

A geneticist and a physician, Dr. Hegele currently treats more than 1,600 patients at the London Health Sciences Centre. To date, his lab has discovered the world's first genetic mutations underlying nine diseases, including Oji-Cree type 2 diabetes and three forms of lipodystrophic diabetes. In total, his lab has also discovered more than 100 mutations in known genes that contribute to high cholesterol, diabetes and heart disease.

Rob Hegele holds a Canada Research Chair in Human Genetics, an Ontario Distinguished Researcher Award and a Career Investigator award from the Heart and Stroke Foundation. His discovery of a rare gene mutation that causes early heart disease was listed in the American Heart Association's Top Ten Scientific Discoveries for 2001, and in 2004 he was the first Canadian recipient of the Jeffrey M. Hoeg Award from the American Heart Association. In 2006 he was honoured by the Genetics Society of Canada with its top national award - the William F. Grant and Peter B. Moens Award of Excellence. He is listed in the ISI database of the top 1% of highly cited scientists in the world.

Rob has been a proud member of the CSATVB since 1989 and he has appreciated the opportunities that his membership has provided for academic interactions with colleagues.

"Flashback" from the 1995 Spring Newsletter



Spinach, Snakes, Abattoir and Academia — An Ocean Apart

Professor Mark W C Hatton, Ph D



For some thirty years Professor Mark Hatton has been engaged in biochemical research as well as teaching university students. His research accomplishments are reflected in over one hundred publications in scientific journals, books and in symposia proceedings.

[The other Co-Editor's note: More recently, Mark Hatton has examined the catabolism of a range of thrombotic plasma proteins in vivo, particularly their distribution and turnover in the balloon-injured rabbit aorta, and also in the rabbit VX-2 tumor. His administrative activities at McMaster University in the fields of graduate education began as a coordinator in 1983 and concluded after two terms as Associate Dean of Graduate Studies (1995-2001).

Having served the CSTAVB over many years, (including proposing the new name for the Society!), he is welcomed back as President Elect and Co-Editor of the news letter]

Co-Editors: Dr. Mary Richardson and Dr. Mark Hatton. McMaster University (Room HSC-2N22C), 1200 Main St. West, Hamilton ON L8N3Z5;

Telephone (905) 525-9140 Ext. 22371;
Fax: (905) 777-7856;
e-mail: mrichard@mcmaster.ca or hattonm@mcmaster.ca

To have your letters or any information of interest included in the Newsletter, please send your material to Mark Hatton at either address (by mail or e-mail).

Letter to the Editors

Dear Editors:

We need to be very active in evaluating new drugs and medical devices that have been on the market for several years since profound side effects may occur over the long term. The investigation of complications of coronary artery stents is one of these cardiovascular therapies that need further monitoring and a better understanding of how the stent affects biologic processes that lead to a re-occlusion of the coronary artery. The original utilization of angioplasty was a bold endeavour. It showed short term therapeutic benefit, however serious restenosis due to plaque growth and/or vessel wall contractions occurred within a few months. The next breakthrough was the deployment of bare metal stents at the sites of angioplasty. This clever approach reduced stenosis significantly by more than half. Finally, human biology was linked to the stent to create drug-eluting stents in which drugs are incorporated into a bio-compatible non-erodable stent polymer which reduced restenosis even further by interfering with cell proliferation in the plaque that had undergone angioplasty. Currently, two drugs of choice are rapamycin and paclitaxel (taxol). Rapamycin is an antimetabolic antibiotic which interferes with the cell cycle, and Paclitaxel interferes with microtubule function due to stabilization of microtubules which disrupt mitosis. Reduction of vascular smooth muscle proliferation is beneficial, however reducing endothelial proliferation delays re-endothelialization and increases the potential of intraluminal thrombosis. Numerous studies, including meta analysis, show either no effect on thrombosis or no effect in the first year and a mild increase in thrombosis beyond one year and up to four years. We now have data from vascular biology studies indicating that both drugs increase endothelial plasminogen activator inhibitor-1, and paclitaxel increases thrombin-induced tissue factor, both pro-thrombotic factors. There is a need for translational research to fully understand how the drug-eluting stents affect thrombosis and whether this costly therapy is truly more beneficial when compared to uncoated stents, especially with respect to long term survival, re-intervention, and incidence of complications of ischemic heart disease. Both drugs are likely to elute over 3 to 4 months so that late thrombotic events could only be secondary to the stent itself or some change induced in the vascular cells that is stable over the long term.

Avrum I. Gotlieb MDCM, FRCPC

Professor and Chair, Department of Laboratory Medicine and Pathobiology, University of Toronto; Director, Vascular Research Laboratory, Toronto General Research Institute, Department of Pathology, University Health Networks, Banting and Best Diabetes Centre, University of Toronto.

Extract from a letter

from **Dr. M. Daria Haust**
Founding President of the Society



In July, the Editors were delighted to receive a lengthy letter from Dr. Haust in which she describes two items of interest to all members: the following is extracted from Dr. Haust's letter:

"Since we were encouraged in your editorial to send news and other items to the attention of the membership (and reminded that this is OUR NEWSLETTER) I wonder whether you would consider to include the

following two items: (1) On May 4, 2007, I was invested by the Governor General, Mme. Michaëlle Jean, at Rideau Hall as an Officer of the Order of Canada and (2) on May 8, 2007, the 4th Haust Lecture (delivered this year by Dr. Peter Davies, a world authority on cardiovascular diseases) established in my name at the Department of Pathology, Queen's University, took place in Kingston with my family and I in attendance"

[Editors' note: On behalf of all members of the society, we do heartily congratulate Dr. Haust on her investiture as an Officer of the Order of Canada and the annual lectureship at Queen's University that now bears her name. These are highly significant milestones in Dr. Haust's magnificent career as a vascular biologist of international repute.]

An update on the M. Daria Haust Research Award

As mentioned in our last Newsletter, the Executive Committee of the Society has recently approved the 'M. Daria Haust Research Award', an annual award to be given to a female scientist who is within the first 10 years of commencing her full-time faculty position. The first competition for the M. Daria Haust Research Award will take place next year, and the deadline for applications will be July 1, 2008. For further details and access to an application form, please consult the 'Grants and Awards' section of the web site (www.csatvb.ca). We are hoping that an announcement of first recipient of the M. Daria Haust Research Award will be given during the CSATVB Scientific Meeting to be held as part of the CCC Meeting in Toronto, October 25-29, 2008.

Report on Whistler Meeting, March, 2007:

"Vascular Matrix Biology and Bioengineering Workshop"

The Vascular Matrix Biology and Bioengineering Workshop, held in Whistler, B.C. from March 15-18, 2007 was "the meeting of the year". Afterwards, many meeting participants declared: "I can't wait for the next one!" Attended by 140 scientists from around the world, the science was excellent, and the meeting had a very "intimate and interactive" format, with lively discussion following all the presentations. The afternoon poster sessions were extremely well-attended, despite the arrival of 15 cm of fresh snow on Friday calling people to the slopes. Co-sponsored by the North American Vascular Biology Organization and the CSATVB, everyone agreed that the organizers, Michelle Bendeck (University of Toronto) and Cecilia Giachelli (University of Washington), had done a great job!

President's Report

This is my last report for the Newsletter as President of the CSATVB. I have found my 2-year term an invaluable learning experience. Without a doubt, the collegial and hardworking qualities of my fellow Council members have made this also an enjoyable experience. I thank them all, for myself and for all members of CSATVB. At our Annual Meeting in late October 2007, Mark Hatton will become President and I wish him success as he leads the society to new things. Mark, as President-elect, has already geared up his role and has contributed in many ways. He and Mary Richardson have done a superb job as co-editors of this Newsletter. In October this year, we also look forward to welcoming other new leaders to our Council. It is through renewal of leadership that our society thrives.

We look forward to another exciting Annual Meeting this year in Quebec City at the Canadian Cardiovascular Congress in October. The Education

Committee, chaired by Bassam Nassar, has organized yet another strong program. A lot of work goes into this and we thank them once again. On the social side, Pierre Julien, Louise Bourassa and Christophe Garenc have arranged a very special evening for us at Chevalier's House, which is part of «Place des Victoires», the first permanent French establishment in North America. There will be a guided historical tour and a fine dinner of high quality French Canadian cuisine. We hope everyone will show up for this much anticipated event.

This year, our Annual Meeting will be preceded by a half-day CSATVB Trainees' Workshop where 4 speakers, 3 from academia and 1 from industry, will provide insights on career opportunities and how to succeed in a chosen scientific career path. We hope to make this an annual event, focusing on other themes of interest to our trainee members in future years. Garry Shen, Stephen Colgan and Karine Blouin have provided exemplary leadership in planning the workshop and Pierre Julien has provided help with logistical matters.

We are fortunate to have been successful in obtaining strong sponsorship

from industry. In the past 4 years, our sponsorship funds have grown 3-4 fold, allowing us to increase our budget and take on more activities. Pfizer Canada Inc. has been our strong supporter for the past 4 years and is our sole Platinum sponsor this year. AstraZeneca Canada Inc and Merck Frosst/Schering Pharma are our Silver sponsors and Solvay Pharma Inc. is sponsoring us at the Friend level. We thank them all for their support.

With stronger support we are able to work on several new initiatives which will enhance the mandate of our society, to improve atherosclerosis and cardiovascular research, education and patient care. These include the establishment of the 'M. Daria Haust Research Award' and the 'CSATVB Scientific Excellence Award', both of which will be awarded for the first time in 2008. We are also working on a membership drive.

Once again, I want to thank members of Council for their generous gift of time and effort on behalf of CSATVB. I encourage members of CSATVB to consider attending our Annual Meeting in Quebec City in October.

Dr. Teik C. Ooi, President

CSATVB Sponsors

Platinum level (\$90,000 or more)	Silver level (\$30,000 - \$59,000)	Friend Level (\$5,000 - \$9,000)
Pfizer Canada Inc. 	AstraZeneca Canada Inc. Merck Frosst-Schering Pharma	Solvay Pharma Inc.

Leadership in Science Forum

Toronto, June 5-6, 2007

The Forum for Trainees and New Investigators, organized by the Institute of Circulatory and Respiratory Health (ICRH) and the Canadian Institutes of Health Research (CIHR) was attended by more than 100 delegates. The objectives included improving

leadership skills, and fostering innovation and excellence aimed at the improvement of health of Canadians. Dr. Peter Liu, the Scientific Director of ICRH, indicated that ICRH aims to promote new creative research talent. To this end, a slate of established researchers and clinical scientists addressed the delegates on how to start a scientific career, apply for a faculty position, apply for research grants and deal with difficulty situations. Key note addresses were given by

Dr. Duncan Stewart (St. Michael's Hospital, Toronto) on cardiology and Dr. Deborah Cook (McMaster University) on critical care including the clinical trials undertaken by her group and collaborators.

The highlights of the Forum were the two leadership workshops. The first, given by Dr. Malcolm Ogborn (University of Manitoba), not only kept the delegates on their toes, thanks to his flying stuffed toys, but

gave information and tips helpful for both basic and clinical scientists. Participants were asked to consider issues that are relevant to accepting or declining a faculty position. Suggested advantages included: liberty to do research; funding for 5 years; good lab space; existing infrastructure; good peers and collaborators; good life-work balance and good technical staff. Extensive teaching load; poor access to good students, and poor mentors were suggested as disadvantages. Dr. Ogborn identified some of the productivity-related issues faced by new investigators which included: unexpected obstacles (including management issues), poor collegial relationships, lack of feedback, limited resources for work, lack of life-work balance and an unsatisfying salary. He suggested that an interviewee should ask why the job opening exists, what are the expectations in research and teaching in the next 1-3 years, and what are the career development prospects over the next 5 years. Graduate studies and postdoctoral fellows should be concerned about research output and opportunities for good experimental science; for Faculty members there should be more focus on organizational management, and time management skills. There was discussion of the various roles of clinical researchers

including the clinical-scientist (qualified as MD, PhD), clinical-investigator (MD, MSc or MD, PhD) and clinician-interested-in-research (MD only). It would have been opportune if Dr. Ogborn had been allotted a second session to review those topics he was unable to cover due to time constraints.

The other leadership workshop was delivered by the CIHR Deputy Director, Dr. Nathalie Gendron. Dr. Gendron talked about making a grant fundable and what to do if it is turned down. She described some of the many minute mistakes and blunders that lead to rejection.

The trainees had a good opportunity during the presentations to interact with the speakers. This interaction was further facilitated during the lunch-with-mentors session. This helped the trainees to discuss their individual questions and concerns with mentors they preferred.

Four simultaneous workshops were held on both afternoons. The topics included: "Setting up and managing your basic science research lab", "Setting up and managing your clinical science lab", "The art of dissemination of information: from posters to papers to media" and "Tips for getting tenure". Interactive discussions within the workshops helped trainees to

receive direct answers from established investigators. The time allotted to these workshops was too short and it is hoped that next year, more time is given to these workshops where trainees can get a direct idea about many of the management and technical issues related to getting a tenure and establishing a research lab.

The Forum also included 27 poster presentations: 6 in respiratory; 7 in brain, blood, critical care, sleep; and 14 in cardiovascular research. A total of 5 awards were made to poster presenters.

CSATVB, as well as a number of other related nation-wide organizations, supported this Forum. Next year the Forum will be held from May 8-10, 2008 at the Le Centre Sheraton Montreal Hotel in Montreal, Quebec. Details can be accessed at the website: <http://www.cibr.ca/e/8663.html>. As in previous years, this Forum has been an immense success and hopefully will remain a major attraction for research students, trainees and new investigators in Canadian institutions in the future.

Garry Shen¹ and M. Nabeel Ghayur²
¹ Department of Internal Medicine, University of Manitoba, Winnipeg R3E 3P4, Manitoba, Canada. Tel: 204-789-3816, Email: gshen@ms.umanitoba.ca
² Department of Medicine, McMaster University, St. Joseph's Hospital, Hamilton L8N 4A6, Ontario, Canada. Tel: 905-522-1155 (x 34327), Email: nghayur@mcmaster.ca

Introducing Dr. Xiao-Yan Wen (CSATVB New Investigator Awardee, 2005)



Dr. Wen is currently an Assistant Professor in the Department of Medicine at the University of Toronto and a research scientist at the McLaughlin Centre for Molecular Medicine and University Health Network. He received his Ph.D. from the Department of Medical Genetics and Microbiology at the University of Toronto in 1995.

Building on his Ph.D. work in which he characterized a mouse transgenic insertional mutation *lpd* (lipid defect), Dr. Wen's group has identified a novel lipase subfamily (known as a phospholipase A1 family) which may play important roles in cardiovascular and other metabolic diseases. His lab has recently knocked out two genes (*lpdl* and *lpdlr*) in this gene family, and full structural and functional characterization of these phospholipases is ongoing. Available data suggest that this gene family plays

important roles in lysophosphatic acid generation and thrombosis. To study the genetic controls of cardiovascular development and hematopoiesis, Dr. Wen has most recently built a state-of-the-art zebrafish facility at University Health Network and is conducting a transposon-based, genome-wide mutagenic gene trapping screen in the zebrafish genome. His lab has strong research interests in areas including: (1) The development of methods in transgenesis and mutagenesis; (2) Lipase function and thrombosis; (3) Genetic control of zebrafish cardiovascular development.

In 2005, Dr. Wen was awarded the New Investigator Grant-in-Aid from CSATVB. In recognition of this award, Dr. Wen will be giving a seminar (entitled: "Roles of Two Novel Phospholipases A1 (lpdl and lpdlr) in Lysophosphatidic Acid Generation and Thrombosis" on October 21 at the upcoming CSATVB Scientific Meeting in Quebec City. An Abstract of his presentation is given in the CSATVB brochure for the Meeting

FINAL PROGRAM

of the Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology (CSATVB) / Société canadienne d'athérosclérose, de thrombose et de la biologie vasculaire (SCATVB) to be held at the CCC Meeting in Quebec City (October 20-24, 2007)

Saturday, October 20

13:00-17:00 Meeting of the Executive & Council

Sunday, October 21

7:45-13:00 CSATVB Trainee Workshop (More details at right)
 14:00-17:00 Poster Presentations
 18:00-23:00 CSATVB Happy Hour and Dinner

Monday, October 22

8:00-9:30 **Oral Session I**
 Includes Presentation by Dr. Xiao-Yan Wen, Recipient of the 2005 New Investigator Grant in Aid: Roles of Two Novel Phospholipases A1 (lpdl and lpdlr) in Lysophosphatidic Acid (LPA) Generation and Thrombosis
 10:00-12:00 **Symposium I**
 Estrogen, Vascular Biology and Atherosclerosis
 Chair: Sandra Davidge
 Edward O'Brien: Modulating Estrogen Receptor Beta and Atherosclerosis
 Ellis Levin: Estrogen Signaling to Prevent Cardiovascular Disease
 Philip Shaul: New Ligands and Protein-Protein Interactions for an Old Receptor
 13:00-15:00 **Symposium II**
 Progenitor cells in Vascular Biology
 Chair: Edward O'Brien
 Duncan Stewart: Genetically Enhanced Endothelial Progenitor Cells for the Treatment of Pulmonary Hypertension: Update on the PHACeT Trial
 Qingbo Xu: Role of Stem Cells in Vascular repair
 Charles E. Murry: Repairing the Infarcted Heart: Roles for Endogenous and Exogenous Stem Cells
 16:00-18:00 **Oral Session II**

Tuesday, October 23

8:00-10:00 **Oral Session III**
 10:30-12:00 **Oral Session IV**
 13:00-15:00 **Symposium III**
 Lessons for Atherosclerosis from Extreme Phenotypes
 President's Symposium Chair: Teik C. Ooi
 Robert Hegel: Riding the Phenotypic Bell Curve and Testing Genes for Holes: The Search for Genetic Determinants of Metabolic Risk Factors
 Jacques Genest: Genetics of High-Density Lipoproteins
 Shailesh B. Patel: Rare Sterol Disorders and Insights
 15:30-16:30 Annual General Meeting



CSATVB Trainee Workshop

To be held on Sunday,
October 21, 2007, 7:45 am-1:00 pm,
at the Morrin Center,

44 Chaussée des Écossais, Québec City (only a short walking distance from the Convention Centre; see the map at www.csatvb.ca)

Chair: Dr. Garry Shen,
Co-Chairs: Dr. Pierre Julien,
Mr. Stephen Colgan

OBJECTIVES:

This workshop aims to assist trainee members in the preparation and development of their scientific careers. The Workshop Committee has invited speakers with academic and industrial backgrounds to give interactive presentations on topics of common interest and chosen by trainees. The workshop will provide an environment for fruitful interactions and discussion between established researchers and trainees.

PRELIMINARY PROGRAM, Sunday October 21st:

7:45 am Registration & continental Breakfast;
 8:30 am Guided tour of the historical, Morrin Center
 9:00 am Welcome: Trainee Advisory Committee
 9:05 am Introduction, Dr. T. Ooi, President CSATVB
 9:10 am A guest speaker from the Pharmaceutical Industry (Pfizer Canada: TBA)
 9:40 am A male guest speaker who is an established researcher in a University setting: Professor Dr. Fernand Labrie
 10:10 am Coffee break
 10:30 am A female guest speaker who is an established researcher in a University setting: Dr. Alexandra Lucas
 11:00 am A young investigator who has recently started a research lab: Dr. Scott Heximer
 11:30 am Questions and answers
 12:00 am Buffet lunch.